Article
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.
Malaria journal - 21 Jan 2020
Massamba Laurencie, Madamet Marylin, Benoit Nicolas, Chevalier Alicia, Fonta Isabelle, Mondain Véronique, Jeandel Pierre-Yves, Amalvict Rémy, Delaunay Pascal, Mosnier Joel, Marty Pierre, Pomares Christelle, Pradines Bruno
Abstract excerpt
BACKGROUND: The drug combination atovaquone-proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone-proguanil treatment failures have been reported. Resistance to cycloguanil, the active metabolite of proguanil, is conferred by multiple mutations in the Plasmodium falciparum dihydrofolate reductase (pfdhfr) and resistance to atovaquone by single...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.